BioXcel Execs Face Investor Suit Over Alzheimer's Drug Probe
By Sydney Price · January 3, 2024, 5:47 PM EST
Top brass at artificial intelligence-driven biopharmaceutical company BioXcel Therapeutics Inc. have been hit with a shareholder derivative suit alleging they took too long to disclose a U.S. Food and Drug Administration...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login